



29th October 2026

To
The Secretary,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001
Scrip Code: 500674

The Secretary,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra-Kurla Complex, Bandra (E),
Mumbai 400 051
Symbol: SANOFI

Sub: Outcome of the Board Meeting of the Company held on Thursday, 29th October 2026

Dear Sir / Madam,

Further to our intimation dated 19th October 2026, we wish to inform you that the Board of Directors, at its meeting held today i.e. Thursday, 29th October 2026, *inter-alia* considered and

- Approved the Unaudited Financial Results for the quarter and nine months ended 30th September 2026.

Accordingly, we enclose a copy of the Limited Review Report, and the Unaudited Financial Results for the quarter and nine months ended 30th September 2026 as required under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"). A press release in this regard has also been enclosed.

An extract of the aforesaid Financial Results will be published in the newspapers in the format prescribed under Regulation 47 of the Listing Regulations.

- Declared an Interim Dividend of Rs. 75/- (Rupees Seventy-Five only) per equity share of the face value of Rs. 10/- (Rupees Ten only) each for the financial year 2026, which shall be paid within the stipulated timelines. Pursuant to Regulation 42 of the Listing Regulations, the Company has fixed Thursday, 5th November 2026 as the "Record Date" for the payment of Interim Dividend to those Members whose names are on the Company's Register of Members on Thursday, 5th November 2026 and those whose names appear as Beneficial Owners as at the close of the business hours on Thursday, 5th November 2026 as per the details to be furnished by the Depositories, viz. NSDL and CDSL, for this purpose.

The Financial Results are being made available on the Company's website on [Financial results - Sanofi India](#).



The meeting of Board of Directors commenced at 2:30 p.m. and concluded at 4:45 p.m.

Please take the above information on record.

Thanking you,

Yours faithfully

For Sanofi India Limited

Haresh

Bachubhai Vala

Digitally signed by
Haresh Bachubhai Vala

Date: 2026.10.29
18:14:35 +05'30'

Haresh Vala

Company Secretary and Compliance Officer

Membership No.: A18246

Encl:a/a

CC:

1. MUFG Intime India Private Limited, Registrar and Share Transfer Agent
2. National Securities Depository Limited ("NSDL")
3. Central Depository Services (India) Limited ("CDSL")

Press Release

Sanofi India delivers strong Q3 2026 performance, led by 9% growth in Diabetes Portfolio resulting in robust profit momentum

Mumbai, October 29th, 2026

Sanofi India Limited announced its financial results for the quarter ended on September 30th, 2026, reporting **domestic net sales** growth of **+2%** and total net sales growth of **4%** compared to the third quarter of 2025.

The **Insulin portfolio** extended its winning run, delivering high single-digit **growth of 9%** in Q3'26 cementing Sanofi's leadership in the Diabetes Injectable segment with a **55% market share**. Lantus®, Toujeo®, and Apidra® led the charge, joined by the strong performance of Soliqua®, the premium offering in the premix diabetes space.

The **public sector** business **surged by 85%**, driven by new accounts opened for innovative analogue segments, further deepening Sanofi's footprint in the diabetes injectable space.

Export sales delivered **good double-digit growth** on the back of a winning strategy, underscoring the resilience of Sanofi India's international operations amid global headwinds.

Strategic partnerships in the Cardiovascular, Oral anti-Diabetes and Central Nervous System segments are progressing and have contributed to incremental market reach. Partnership revenues were broadly stable in Q3 2026, with the expanded commercial footprint showing an acceptable return on investment, while continued focus is needed to strengthen performance.

Profits before tax and exceptional items rose 22% to INR 158 crores, compared to INR 130 crores in the third quarter of 2025. Profit before tax as a percentage of net sales **improved to 34% in Q3 2026**, up from 29% in Q3 2025.

This gross margin improvement reflects a favorable product mix, a one-off reversal of provisions, and disciplined cost management through operational efficiencies, with **operating expenses** (employee cost + other expenses) **declining 8%** compared to

sanofi

the third quarter of 2025.

Deepak Arora

Managing Director

"Our diabetes business is firmly in momentum, growing in double digits quarter-on-quarter (at a YTD-level). Sanofi India's PAT has also grown in double digits (at a YTD-level), capped by a strong Q3'26 PAT growth of 54% v/s Q3'25. These results reflect a laser-focused strategy that keeps patients at the center of every decision we make.

Our acceleration in the public sector shows that we are not just growing, we are widening access to innovative therapies across the country.

*With a **55% value share**, a **growth of 14%** in YTD 2026, and a modernized go-to-market model, our **diabetes injectable segment** is setting the foundation for sustainable, long-term value creation for the times to come.*

*As we celebrate 70 years of Sanofi in India, we remain committed to giving back to our communities through educational, awareness, diagnostic, and capability-building initiatives. Our KIDS Program (Kids & Diabetes in School) has reached **3500+ schools** to date, **educating 6,00,000 children** across Goa, Uttar Pradesh & Madhya Pradesh (MP). Over the last quarter, the KiDS program was **piloted in 2 districts** (Berasia & Phanda) of Bhopal (MP) and through 2026, our aim is to train 600+ teachers & ~40,000+ children in understanding diabetes and living a healthy lifestyle.*

*Furthermore, our Medical Mobile Units continue to raise health awareness, as they are screening for Non-Communicable Diseases (NCDs namely diabetes, hypertension & oral cancer), providing education, screening, diagnosis, free-of-cost treatment and giving timely referrals to government health centers; having touched the lives of **7,80,000 beneficiaries** across 11 districts of Maharashtra."*

Sanofi in India

Present in India for nearly seven decades, Sanofi has earned the trust of customers and stakeholders for its commitment to promoting health. As Sanofi chases the miracles of science to improve people's lives, it continues to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building.

Sanofi's India Charitable Access Program (InCAP) is the country's longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. Sanofi conducts clinical trials in India, so that the country can have quicker access to the latest from the company's global pipeline. Sanofi India's world-class manufacturing site in Goa produces for people in India and 24+ other countries. Sanofi has located one of its Global Capability Center in Hyderabad, India, which serves as a global talent hub, providing a broad range of services across Sanofi's worldwide operations.

Sanofi (India) is a certified 'Great Place to Work' (2026-2027) and is recognized by the 'Top® Employers Institute' – a global authority that honours excellence in people practices from 2019-2024. Sanofi's local entities include Sanofi India Limited (SIL - listed entity), and Sanofi Healthcare India Pvt. Ltd. (SHIPL).

For more information, visit: www.sanofi.com/en/india, [LinkedIn](#) and [X](#).

Media Relations

Vinifer Gandhi | vinifer.gandhi@sanofi.com

Price Waterhouse & Co Chartered Accountants LLP

Review Report

To
The Board of Directors
Sanofi India Limited
CTS No. 117-B, L&T Business Park,
Saki Vihar Road, Powai,
Mumbai 400 072

1. We have reviewed the unaudited financial results of Sanofi India Limited (the “Company”) for the quarter ended September 30, 2026 and the year to date results for the period January 01, 2026 to September 30, 2026, which are included in the accompanying ‘Statement of Unaudited Financial Results for the quarter and nine months ended September 30, 2026’ (the “Statement”). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations, 2015”), which has been digitally signed by us for identification purposes. The Statement is the responsibility of the Company’s Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/E-300009

ARUNKUMAR RAMDAS Digitally signed by
ARUNKUMAR RAMDAS
R RAMDAS Date: 2026.10.29
18:06:13 +05'30'

Arunkumar Ramdas
Partner
Membership Number: 112433
UDIN: 26112433NBGNFC9531

Place: Mumbai
Date: October 29, 2026

Price Waterhouse & Co Chartered Accountants LLP, 252, Veer Savarkar Marg, Shivaji Park, Dadar (West)
Mumbai - 400 028
T: +91 (22) 66697508

Registered office and Head office: Plot No. 56 & 57, Block ON, Sector-V, Salt Lake, Kolkata - 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E300009 (ICAI registration number before conversion was 304026E)

SANOFI INDIA LIMITED

Registered Office : Sanofi House, C.T.S No - 117-B, L & T Business Park, Saki Vihar Road, Powai, Mumbai 400 072.

Corporate Identity Number: L24239MH1956PLC009794

Tel no: (91-22) 28032000 Fax No: (91-22) 28032846

Website: www.sanofiindia ltd.com Email: igrc.sil@sanofi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2026

Particulars	Quarter ended 30.09.2026	Quarter ended 30.06.2026	Quarter ended 30.09.2025	Nine Months ended 30.09.2026	Nine Months ended 30.09.2025	Year ended 31.12.2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1. Revenue from Operations	4,917	4,377	4,754	14,017	14,176	18,374
2. Other Income	55	62	49	161	169	197
3. Total Income (1+2)	4,972	4,439	4,803	14,178	14,345	18,571
4. Expenses						
(a) Cost of Materials Consumed	736	573	533	1,812	1,911	2,464
(b) Purchases of stock-in-trade	2,274	1,589	2,698	5,345	3,895	5,140
(c) Changes in Inventories of work-in-progress, stock-in-trade and finished goods	(630)	90	(832)	(182)	1,085	1,368
(d) Employee benefits expense	397	446	419	1,271	1,406	1,853
(e) Finance costs	2	3	4	8	11	17
(f) Depreciation and amortisation expense	88	89	91	267	278	373
(g) Other expenses	528	526	594	1,578	1,869	2,636
Total Expenses	3,395	3,316	3,507	10,099	10,455	13,851
5. Profit before exceptional item and tax (3-4)	1,577	1,123	1,296	4,079	3,890	4,720
6. Exceptional item (Refer note 3)	-	-	(273)	-	(273)	(273)
7. Profit before tax (5+6)	1,577	1,123	1,023	4,079	3,617	4,447
8. Income tax expense						
Current Tax	407	297	312	1,047	1,019	1,229
Deferred Tax	3	(9)	(49)	4	(52)	(49)
9. Profit for the period / year (7-8)	1,167	835	760	3,028	2,650	3,267
10. Other comprehensive income (OCI) (Net of Tax)	-	-	-	-	-	17
11. Total comprehensive income for the period / year (9+10)	1,167	835	760	3,028	2,650	3,284
12. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	230	230	230	230
13. Other equity	-	-	-	-	-	7,262
14. Basic and diluted earnings per share (not annualised) (in ₹)	50.67	36.26	32.99	131.48	115.06	141.85

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated October 29, 2026

ARUNKUMAR RAMDAS Digitally signed by
ARUNKUMAR RAMDAS
Date: 2026.10.29
18:06:34 +05'30'

Deepak Arora Digitally signed by
Deepak Arora
Date: 2026.10.29
17:52:37 +05'30'

Notes:

1. The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on October 29, 2026. The statutory auditors have carried out a limited review of the above results for the quarter and nine months ended September 30, 2026.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
3. Exceptional item relate to personnel separation costs of ₹273 million for the quarter and nine months ended September 30, 2025, and for the year ended December 31, 2025.
4. An interim dividend of ₹ 75 per equity share of ₹ 10 for the year 2026 was declared at the meeting of the Board of Directors of the Company held on October 29, 2026.
5. The Company has a single business segment namely 'Pharmaceutical Business'.

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated October 29, 2026

**ARUNKUMAR
RAMDAS**

October 29, 2026

Digitally signed by
ARUNKUMAR RAMDAS
Date: 2026.10.29 18:06:56
+05'30'

SANOFI INDIA LIMITED

**Deepak
Arora**

**DEEPAK ARORA
MANAGING DIRECTOR
DIN: 07495638**

Digitally signed
by Deepak Arora
Date: 2026.10.29
17:52:04 +05'30'